Nhoroondo ye Array BioPharma Inc, binimetinib, Braftovi, encorafenib, Mektovi, Pfizer
Encorafenib ine binimetinib inotenderwa neFDA kuti irapwe metastatic isiri-diki cell cancer yemapapu ine BRAF V600E shanduko.
Chikafu neDrug Administration (FDA) yakatendera Encorafenib (Braftovi, Array BioPharma Inc., inotsigirwa nePfizer) uye binimetinib (Mektovi, Array BioPharma Inc.) muna Mbudzi 2023 semishonga inogona kushandiswa kugadzirisa.
Bosulif, Bosutinib, chisingaperi myelogenous leukemia, CML, Pfizer
Bosutinib inotenderwa neFDA kune varwere vevana vane chisingaperi myelogenous leukemia
Nov 2023: Kune varwere vevana vane gore rimwe chete uye pamusoro vane chisingaperi chikamu (CP) Ph + chisingaperi myelogenous leukemia (CML), ingave ichangobva kuongororwa (ND) kana inopokana kana kusashivirira (R / I) kune yakapfuura kurapwa, iyo Chikafu uye Drug Admini. .
Pfizer, TALAPRO-2, Talazoparib
Talazoparib ine enzalutamide inotenderwa neFDA yeHRR gene-mutated metastatic castration-resistant cancer cancer.
July 2023: The Food and Drug Administration cleared talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC). TALAP..
ADVL0912, anaplastic lymphoma kinase, lymphoma, NCT00939770, Pfizer, Xalkori
Crizotinib inotenderwa neFDA kune ALK-positive inflammatory myofibroblastic tumor
Chikunguru 2022: Crizotinib (Xalkori, Pfizer Inc.) yakapihwa mvumo neFood and Drug Administration (FDA) yekurapa varwere vakuru nevana vane makore 1 ezera uye vakuru vakawanikwa vaine kusarongeka, kudzokororwa.
ALK, B7461006, crizotinib, Lorbrena, lorlatinib, NCT03052608, Pfizer, Ventana ALK, Ventana Medical Systems
Lorlatinib yakagamuchirwa neDFA yekurapa metastatic ALK-positive NSCLC.
Nyamavhuvhu 2021: Lorlatinib (Lorbrena, Pfizer Inc.) akagamuchira mvumo yenguva dzose yeDAA kuvarwere vane metastatic isiri-diki kenza yemapapu kenza (NSCLC) vane mamota ane aplastic lymphoma kinase (ALK) -inotaridzika, sekugadzwa neiyo FDA-app ..
anaplastic lymphoma kinase, B7461006, CDx Assay, Zvokudya uye Drug Administration, Lorbrena, lorlatinib, NCT03052608, NSCLC, Pfizer, Ventana ALK, Ventana Medical Systems
Lorlatinib yakagamuchirwa neDFA yekurapa metastatic ALK-positive NSCLC
Nyamavhuvhu 2021: Lorlatinib (Lorbrena, Pfizer Inc.) akagamuchira mvumo yenguva dzose yeDAA kuvarwere vane metastatic isiri-diki kenza yemapapu kenza (NSCLC) vane mamota ane aplastic lymphoma kinase (ALK) -inotaridzika, sekugadzwa neiyo FDA-app ..
Bharat Biotech, Coronavirus, Covaxin, Covid, Mushonga unobetsera kudzivirira covid, Covishield, Pfizer
COVID-19 Vaccine - Zvese zvawaida kuziva
Dr. Julie Gralow vanopindura mibvunzo pamusoro peCOVID-19 vaccine. Tingave sei nechokwadi chekuti majekiseni akachengeteka kana akagadzirwa uye akabvumidzwa munguva pfupi yakadai?